Noema Pharma

biotech · Basel, CH · noemapharma.com

Clinical-stage Swiss biotech targeting CNS disorders.

Founders

Luigi Costa (Italy · ♂) — A pharma executive recruited by Sofinnova Partners, he co-founded Noema Pharma in 2019 to in-license shelved Roche CNS assets and was its founding CEO before stepping down after three years.
George Garibaldi (♂) — A former Roche VP of neuroscience development, he co-founded Noema as Chief Medical Officer to advance mid-stage CNS drug candidates in-licensed from Roche.

People & leadership

Amine Tahiri VP Medical & Development Strategy

Shares the most investors with (number = shared investors):

Date	Round	Amount
Dec 2024	Series B Swiss biotech Noema Pharma closed its Series B at 147M USD with EQT Life Sciences joining, to fund four Phase 2 CNS trials.	$147M
Mar 2023	Series B Noema Pharma raised an oversubscribed CHF103M Series B co-led by Forbion and Jeito Capital, with PMC Enterprises, Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus.	$103.5M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.